Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine

Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as a potential treatment for follicular NHL. We have recently reported that galiximab signals B-NHL cells in vitro and inhibits cell growth and sensitizes resistant tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: HARIHARAN, KANDASAMY, CHU, PETER, MURPHY, TRACEY, CLANTON, DANA, BERQUIST, LISA, MOLINA, ARTURO, HO, STEFFAN N., VEGA, MARIO I., BONAVIDA, BENJAMIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981005/
https://www.ncbi.nlm.nih.gov/pubmed/23764770
http://dx.doi.org/10.3892/ijo.2013.1986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981005/
https://www.ncbi.nlm.nih.gov/pubmed/23764770
http://dx.doi.org/10.3892/ijo.2013.1986

Ejemplares similares